EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, it has been demonstrated that chronic myeloid leukemia (CML) stem cells rely on EZH2 for self-renewal and disease maintenance and that EZH2 inhibition in combination with targeting of BCR-ABL can be utilized to eradicate these disease-initiating cell populations in a pre-clinical setting [134,135].